Yahoo Web Search

  1. Should You Buy AstraZeneca PLC (LON:AZN) For Its Dividend?

    Simply Wall St. via Yahoo FinanceSep 11 12:57 PM

    Today we'll take a closer look at AstraZeneca PLC (LON:AZN) from a dividend investor's perspective. With AstraZeneca yielding 3.3% and having paid a dividend for over 10 ...

  2. AstraZeneca PLC AZN announced that it has secured an approval from China for the label expansion of its marketed drug Tagrisso (osimertinib) for the first-line treatment of adult ...

  3. Meanwhile, Pfizer PFE, Allergan AGN and Roche RHHBY provided regular pipeline/regulatory updates J&J JNJ, AstraZeneca AZN and Eli Lilly LLY presented data from studies at medical conferences ...

  4. Causeway International Value Fund Buys 2 Stocks in 2nd Quarter

    GuruFocus.com via Yahoo FinanceSep 03 17:18 PM

    (HKSE:00941), Rolls-Royce Holdings PLC (LSE:RR.), Volkswagen AG (XTER:VOW3), AstraZeneca PLC (LSE:AZN) and Ingenico Group SA (XPAR:ING). Causeway's $6.47 billion equity ...

  5. The biotech space saw muted activity in the week ended Aug. 30. Among the notable news of the week: Amgen, Inc. (NASDAQ: AMGN )'s $13.4-billion deal to buy the psoriasis drug Otezla from Celgene Corporation ...

  6. This week, Allergan AGN settled with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse. The European Commission granted approvals ...

  7. International Association for the Study of Lung Cancer (IASLC) 2019 World Conference - Sept. in Barcelona, Spain 32nd European College of Neuropsychopharmacology (ECNP) Congress – Sept. in Copenhagen ...

  8. Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

    Zacks via Yahoo FinanceSep 13 14:08 PM

    GlaxoSmithKline plc GSK announced that the FDA has granted approval to Nucala as an add-on treatment for severe eosinophilic asthma in the pediatric patient population, aged six to 11 ...

  9. Ardelyx is a biopharma company developing drugs for cardiorenal diseases. The Fremont, California-based company was launched in 2007 and does not have a commercial product on the market. The company's revenues so far have mostly come from licensing.

  10. ACADIA Surges on Early Success of Nuplazid Dementia Study

    Zacks via Yahoo FinanceSep 10 15:41 PM

    ACADIA Pharmaceuticals Inc. ACAD announced that Nuplazid (pimavanserin) met the primary endpoint by showing statistically significant superiority over placebo in increasing the time to relapse ...